immuno-oncology therapy News
-
Actym Therapeutics Announces Issuance of US Patent
Actym Therapeutics, a privately-held biotechnology company focused on the discovery and development of novel immuno-oncology therapies to treat cancer, announced today that the United States Patent and Trademark Office (USPTO) has granted a patent that protects the company's therapeutic technology platform. "The issuance of US patent 11,168,326 recognizes the novelty and uniqueness of our ...
-
Leading clinical immunotherapies developer Ramy Ibrahim joins bit.bio as Chief Medical Officer
biotech firm bit.bio today announces the appointment of Dr Ramy Ibrahim, MD, as Chief Medical Officer. The addition of a Chief Medical Officer is in line with the company’s plans and commitment to transition into a clinical company. Ramy joins from the Parker Institute for Cancer Immunotherapy where he was Chief Medical Officer and will remain on the board. At the Parker Institute, he ...
By bit.bio
-
T3 Pharmaceuticals wins highest endowed award for startup companies in Switzerland
T3 Pharmaceuticals AG – a biotech company in Basel focused on immunooncology – wins the W.A. de Vigier Foundation’s highest endowed award for startup companies in Switzerland with CHF 100,000 in prize money. «We are honored to receive the W.A. de Vigier Foundation’s oldest and highest endowed sponsorship award and would like to thank the foundation and foundation ...
-
Actym Therapeutics CEO Dr. Christopher Thanos named one of the “Top 25 Biotech CEOs of 2022”
We are pleased to announce that Actym Therapeutics’ President and CEO, Dr. Christopher Thanos, has been named one of the “Top 25 Biotech CEOs of 2022” by the Healthcare Technology Report. Hundreds of nominations were submitted this year to The Healthcare Technology Report and winners were selected based on leaders’ contributions to the advancement of medicine and the ...
-
Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer
Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors. "Chan has significant ...
-
Actym Therapeutics Announces Lead Candidate for Clinical Development, Presentation at SITC
Actym Therapeutics today announced that ACTM-838 has been selected as a lead clinical development candidate for the treatment of solid tumors. ACTM-838 is based on the company's immunotherapy platform called STACT (S. Typhimurium-Attenuated Cancer Therapy), which delivers multiplexed immuno-modulatory payloads directly to tumor-resident immune cells. ACTM-838 is a STACT strain that encodes ...
-
Dako, an Agilent Technologies Company, Announces FDA Approval of New Test for Lung Cancer Patients
Dako, an Agilent Technologies company and a worldwide provider of cancer diagnostics, today announced the U.S. Food and Drug Administration has approved a new test that can identify PD-L1 expression levels on the surface of non-small cell lung cancer tumor cells and provide information on the survival benefit with OPDIVO® (nivolumab) for patients with non-squamous NSCLC. Dako developed the ...
-
MH Guide 5.0: Software for therapy planning in precision oncology, now available with a comprehensive update
Molecular Health has launched the latest version of its analysis software MH Guide. This software, which is used by pathology laboratories and molecular tumor boards, now has improved search capabilities to identify patient- relevant clinical studies. With the VCF Adapter Suite, Molecular Health also offers a conversion tool to easily integrate data from the most common NGS sequencing systems. ...
-
< Back to Home Actym Therapeutics and Wacker Biotech Sign Manufacturing Contract for Actym`s Lead Candidate for the Treatment of Solid Tumors
Actym Therapeutics, a biotechnology company focused on the discovery and development of novel therapies intended to transform the treatment of cancer, and Wacker Biotech announced today that they have signed a contract for the manufacturing of Actym's lead clinical candidate, ACTM-838, for the treatment of solid tumors. Under the terms of the agreement, Wacker Biotech will initiate GMP (Good ...
-
Celularity Appoints Industry Leader Diane Parks to its Board of Directors
Celularity Inc. (Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous ...
-
Actym Therapeutics Announces Expansion of Scientific Advisory Board
BERKELEY, Calif., Jan. 13, 2021 /PRNewswire/ -- Actym Therapeutics Inc., a privately-held company focused on the development of immunotherapies to treat cancer from its attenuated, microbial-based STACT platform, announced today the appointments of Dr. Lawrence Fong, M.D. and Dr. Michel Streuli, Ph.D., to its Scientific Advisory Board (SAB). Actym's SAB comprises world-renowned subject matter ...
-
PsiOxus Therapeutics Announces Clinical Trial with Third Cancer Gene Therapy Treatment and Appointment of New Chief Medical Officer.
March 05, 2020 – OXFORD, UK – PsiOxus® Therapeutics, Ltd. (PsiOxus), the gene therapy for cancer company, today announced that it has started a clinical trial with NG-641, a four transgene tumor-microenvironment modifying cancer gene therapy. This is the first time that a tumor- specific virus containing four different therapeutic transgenes has been administered to cancer ...
-
Actym Therapeutics Announces Significant Expansion of Senior Leadership
Actym Therapeutics, a privately held biotechnology company developing STACT, a novel therapeutic platform that delivers immunomodulatory payloads to solid tumors after IV dosing, announced today the significant expansion of its senior leadership team. Dr. Julie Cherrington joins as BOD Chair, James Stutz joins as Chief Business Officer, and Dr. Omkar Joshi joins as Vice President, Technical ...
-
Thermo Fisher Scientific Acquires Programmable Dye Platform Pioneer Phitonex
Thermo Fisher Scientific, the world leader in serving science, today announced it has completed the acquisition of Phitonex, Inc., a Durham, North Carolina-based company that has pioneered a spectral dye platform for high-resolution biology applications designed to accelerate research and development in cell therapy, immuno-oncology and immunology research. Phitonex's product offering will enable ...
-
Thermo Fisher Scientific Acquires Leading Cell Sorting Technology from Propel Labs
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced it has acquired cell sorting technology assets from Propel Labs, a wholly-owned subsidiary of SIDIS Corp. Under the terms of the agreement, the recently introduced Bigfoot Spectral Cell Sorter and approximately 40 employees will become part of Thermo Fisher's Biosciences business. Propel Labs will ...
-
Immunai Raises $60M to Reprogram Immunity
Immunai, a New York and Tel Aviv based biotech company, announced today $60M in funding, increasing the company’s total funding-to-date to over $80M. Immunai integrates multi-omic single-cell analytics and machine learning to identify novel immunological insights that lead to the discovery and development of more effective and targeted immunotherapies. The Series A round was led by ...
By Immunai
-
Agnieszka Blum, MD, PhD has been promoted to the Management Board of Ardigen to strengthen drug discovery expertise
Ardigen, a global leader in artificial intelligence for drug discovery, is proud to announce that Agnieszka Blum, MD, PhD has joined the company’s Board of Management. She brings with her extensive knowledge and experience in the field of Immuno-Oncology and drug discovery, which is strategic for Ardigen’s development. Agnieszka Blum, MD, PhD will continue her mission as the General ...
By Ardigen
-
Immatics and Bristol Myers Squibb Enter Into Global Exclusive License for Immatics’ TCR Bispecific Program IMA401
Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, and Bristol Myers Squibb (NYSE: BMY), today announced that they have entered into a license, development and commercialization agreement (the “agreement”) for Immatics’ TCR Bispecific candidate, ...
-
Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting
Bayer presents first Phase 1 results from its most advanced clinical Immuno-Oncology program, aryl hydrocarbon receptor (AhR) inhibitor BAY2416964 New preclinical data on Bayer’s DGK zeta inhibitor being featured in oral presentation in New Drugs on the Horizon session New preclinical data on mutEGFR HER2 program, currently in Phase 1, will be presented Bayer progresses novel research ...
By Bayer AG
-
Ncardia and Cellistic recruit Gustavo Mahler to lead the businesses through their next phase of growth
We are excited to announce that Gustav Mahler is hired as the Chief Executive Officer of Ncardia and Cellistic and will join the Board of Directors. Our founder Stefan Braam will assume the role of President and Chief Technical Officer and will remain in the board of directors. With this shift in our leadership team, we hope to continue our journey of rapid growth and expansion delivering world ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you